Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (361-370 of 609) with videos related to

Pageof 61
Sort By:
The Journal of Rheumatology|July 2, 2004
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanerceptPhillip J Mease, Christopher T Ritchlin, Richard W Martin, et al.
Revista Chilena De Pediatria|March 1, 1984
[Toxoplasmosis in children treated with immunosuppressive drugs]B Gottlieb, H Reyes, P Herskovic, et al.
Infection Control and Hospital Epidemiology|August 31, 2023
Discordant antimicrobial susceptibility and polymerase chain reaction (PCR) testing in a <i>Klebsiella pneumoniae</i> isolate with a carbapenemase geneLucy S Witt, Alex Page, Eileen M Burd, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trialRobert E Kalb, Andrew Blauvelt, Howard L Sofen, et al.
The Journal of Dermatological Treatment|December 25, 2018
Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventionsLisa Prussick, Sarah Tonelli, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
The Journal of Experimental Medicine|July 1, 1994
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapyV P Vallat, P Gilleaudeau, L Battat, et al.
Annals of the Rheumatic Diseases|May 6, 2017
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisPhilip J Mease, Alice B Gottlieb, Désirée van der Heijde, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Pageof 61

Showing results (361-370 of 609) with videos related to

Sort By:
Pageof 61
The Journal of Rheumatology|July 2, 2004
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanerceptPhillip J Mease, Christopher T Ritchlin, Richard W Martin, et al.
Revista Chilena De Pediatria|March 1, 1984
[Toxoplasmosis in children treated with immunosuppressive drugs]B Gottlieb, H Reyes, P Herskovic, et al.
Infection Control and Hospital Epidemiology|August 31, 2023
Discordant antimicrobial susceptibility and polymerase chain reaction (PCR) testing in a <i>Klebsiella pneumoniae</i> isolate with a carbapenemase geneLucy S Witt, Alex Page, Eileen M Burd, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trialRobert E Kalb, Andrew Blauvelt, Howard L Sofen, et al.
The Journal of Dermatological Treatment|December 25, 2018
Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventionsLisa Prussick, Sarah Tonelli, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.
The Journal of Experimental Medicine|July 1, 1994
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapyV P Vallat, P Gilleaudeau, L Battat, et al.
Annals of the Rheumatic Diseases|May 6, 2017
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisPhilip J Mease, Alice B Gottlieb, Désirée van der Heijde, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Pageof 61